We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+8.33%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$180M
AUM Growth
-$16.6M
Cap. Flow
-$8.49M
Cap. Flow %
-4.71%
Top 10 Hldgs %
42.71%
Holding
128
New
34
Increased
5
Reduced
15
Closed
37

Top Buys

Rank Stock Value
1
AVDL
Avadel Pharmaceuticals
AVDL
+$4.11M
2
PEN icon
Penumbra
PEN
+$4.08M
3
ATEC icon
Alphatec Holdings
ATEC
+$3.82M
4
INSP icon
Inspire Medical Systems
INSP
+$3.16M
5
VREX icon
Varex Imaging
VREX
+$3.14M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$6.85M
2
PEPL
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
+$6.47M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$5.29M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$4.95M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$4.32M

Sector Composition

Rank Sector Weight
1 Healthcare 85.22%
2 Financials 3.64%
3 Technology 0.85%
4 Communication Services 0.51%
5 Materials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PEPG icon
101
PepGen
PEPG
$197M
– –
-40,000
Closed -$535K
PLRX icon
102
Pliant Therapeutics
PLRX
$65M
– –
-100,000
Closed -$1.93M
QTRX icon
103
Quanterix
QTRX
$190M
– –
-224,800
Closed -$3.11M
RXST icon
104
RxSight
RXST
$260M
– –
-50,586
Closed -$641K
RYTM icon
105
Rhythm Pharmaceuticals
RYTM
$7.96B
– –
-170,000
Closed -$4.95M
SAGE
106
DELISTED
Sage Therapeutics
SAGE
– –
-50,000
Closed -$1.91M
SIBN icon
107
SI-BONE Inc
SIBN
$834M
– –
-195,000
Closed -$2.65M
TERN
108
DELISTED
Terns Pharmaceuticals
TERN
– –
-70,000
Closed -$713K
TGTX icon
109
CALL
TG Therapeutics
TGTX
$7.62B
– –
-100,000
Closed -$1.18M
TLRY icon
110
CALL
Tilray
TLRY
$622M
– –
-760
Closed -$20.4K
TNDM icon
111
Tandem Diabetes Care
TNDM
$1.56B
– –
-90,000
Closed -$4.05M
TSHA icon
112
Taysha Gene Therapies
TSHA
$1.89B
– –
-359,051
Closed -$811K
TVRD
113
Tvardi Therapeutics
TVRD
$23.4M
– –
-5,443
Closed -$2.1M
NVRO
114
DELISTED
NEVRO CORP.
NVRO
– –
-76,000
Closed -$3.01M
ITCI
115
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-100,000
Closed -$5.29M
SYRS
116
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-315,070
Closed -$1.13M
WAVSU
117
DELISTED
Western Acquisition Ventures Corp. Unit
WAVSU
– –
-100,000
Closed -$1.1M
ARYD
118
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
– –
-100,000
Closed -$1.01M
MBTCR
119
DELISTED
Nocturne Acquisition Corporation Right
MBTCR
– –
-500,000
Closed -$38.9K
KRTX
120
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-22,000
Closed -$4.32M
SLGC
121
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
– –
-310,000
Closed -$778K
MURFU
122
DELISTED
Murphy Canyon Acquisition Corp. Unit
MURFU
– –
-100,000
Closed -$1.02M
ZEV
123
DELISTED
Lightning eMotors, Inc.
ZEV
– –
-29,093
Closed -$213K
GSRMU
124
DELISTED
GSR II Meteora Acquisition Corp. Unit
GSRMU
– –
-50,000
Closed -$529K
TRKA
125
DELISTED
Troika Media Group, Inc. Common Stock
TRKA
– –
-106,906
Closed -$310K
2 3 4
5
6

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
ICP
Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return

Altium Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Altium Capital Management held 128 positions worth $180M, down 8.5% from $197M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Altium Capital Management withdrew a net $8.49M in Q1 2023, closing 37 positions and reducing 15 holdings. Its most notable exit was Akero Therapeutics, an estimated $6.85M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 89% a quarter earlier, followed by Financials and Technology.

Against the trend, Altium Capital Management opened a new position in Avadel Pharmaceuticals worth $4.58M.

  • Altium Capital Management's largest Q1 2023 buy was Avadel Pharmaceuticals: 500,000 shares worth $4.58M.
  • Altium Capital Management added most to CTI BioPharma Corp. (DE) Common Stock in Q1 2023, an estimated $2.08M increase.
  • Altium Capital Management's biggest Q1 2023 reduction was PepperLime Health Acquisition Corporation Class A Ordinary Share, cutting an estimated $6.47M.
  • Altium Capital Management fully exited Akero Therapeutics in Q1 2023, selling an estimated $6.85M.
  • Altium Capital Management's ten largest holdings make up 43% of its $180M portfolio in Q1 2023.
  • Altium Capital Management opened 34 new positions and closed 37 in Q1 2023.
  • Altium Capital Management's portfolio value fell 8.5% quarter-over-quarter to $180M.

Based on Altium Capital Management's 13F filing for Q1 2023, filed 15 May 2023.